Relatório de Análise do Tamanho, Participação e Tendências do Mercado Global da Síndrome Respiratória do Oriente Médio (MERS) – Visão Geral do Setor e Previsão até 2033

Tamanho do mercado da Síndrome Respiratória do Oriente Médio (MERS)

• O mercado global da Síndrome Respiratória do Oriente Médio (MERS) foi avaliado em US$ 1,20 bilhão em 2025  e deverá atingir  US$ 2,09 bilhões até 2033 , com uma taxa de crescimento anual composta (CAGR) de 7,2% durante o período de previsão.
• O crescimento do mercado é impulsionado principalmente pelo foco crescente na vigilância de doenças infecciosas , pelo aumento das iniciativas de preparação do sistema de saúde e pelos esforços contínuos de pesquisa voltados para o aprimoramento de diagnósticos, terapias e estratégias de prevenção de infecções por MERS-CoV nas regiões afetadas.
• Além disso, o aumento dos investimentos em infraestrutura de saúde pública, aliado à maior conscientização entre profissionais de saúde e governos sobre doenças zoonóticas emergentes, está fortalecendo as capacidades de detecção e resposta precoces. Esses fatores convergentes estão acelerando a adoção de ferramentas de diagnóstico avançadas e protocolos de tratamento, apoiando, assim, a expansão geral do mercado de MERS.

Análise de mercado da Síndrome Respiratória do Oriente Médio (MERS)

• O mercado da Síndrome Respiratória do Oriente Médio (MERS), que engloba terapias experimentais e vacinas candidatas, concentra-se principalmente no desenvolvimento de produtos biológicos direcionados e soluções preventivas, como REGN3048, REGN3051, GLS-5300 e outros produtos em desenvolvimento, com o objetivo de neutralizar o vírus MERS-CoV e reduzir a gravidade da doença e o risco de transmissão.
• A crescente demanda por soluções relacionadas à MERS é impulsionada principalmente pelo aumento dos investimentos em pesquisa e desenvolvimento de anticorpos monoclonais e plataformas de vacinas de DNA, pelo aumento do financiamento governamental e institucional para doenças infecciosas emergentes e pelas avaliações clínicas em andamento de terapias candidatas para atender às necessidades médicas não atendidas em regiões propensas a surtos.
• A América do Norte dominou o mercado da Síndrome Respiratória do Oriente Médio (MERS) com a maior participação na receita, de 40% em 2025, impulsionada por uma forte infraestrutura de P&D, recursos avançados de biotecnologia e participação ativa em ensaios clínicos.
• Prevê-se que a região Ásia-Pacífico testemunhe o crescimento mais rápido no mercado da Síndrome Respiratória do Oriente Médio (MERS) durante o período de previsão, devido à expansão das capacidades de pesquisa biofarmacêutica, ao aumento das colaborações com organizações de pesquisa globais e ao crescimento das iniciativas de preparação para gerenciar possíveis surtos de doenças infecciosas.
• O segmento parenteral dominou o mercado da Síndrome Respiratória do Oriente Médio (MERS) em 2025, com uma participação de 70,2%, devido à predominância de anticorpos monoclonais injetáveis ​​e vacinas candidatas que requerem administração intravenosa ou intramuscular para otimizar a biodisponibilidade, a ação sistêmica rápida e a geração de uma resposta imune eficaz.

Escopo do relatório e segmentação do mercado da Síndrome Respiratória do Oriente Médio (MERS)

Middle East Respiratory Syndrome (MERS) Market Trends

“Advancements in Vaccine Development and Monoclonal Antibody Research”

• A significant and accelerating trend in the global MERS market is the ongoing development of advanced vaccine platforms and monoclonal antibody therapies targeting MERS-CoV, aimed at improving prevention and treatment outcomes in high-risk populations
• For instance, candidates such as GLS-5300 and REGN3048/REGN3051 are being evaluated for their ability to induce immune responses and neutralize the virus, highlighting progress in biologics and DNA vaccine technologies
• Increasing application of next-generation sequencing and molecular diagnostics is enhancing the ability to rapidly identify viral strains and track mutations, supporting more effective outbreak response strategies. Furthermore, integration of advanced immunological profiling tools is enabling researchers to better understand immune responses and optimize therapeutic design
• The expansion of global collaboration between research institutes, governments, and pharmaceutical companies is facilitating data sharing, clinical trials, and accelerated development timelines, creating a more coordinated approach to combating MERS. Through centralized research initiatives, stakeholders are working toward improving preparedness and response capabilities
• Growing adoption of AI and bioinformatics tools in drug discovery is helping accelerate the identification of potential therapeutic targets and streamline candidate screening processes, reducing early-stage development timelines
• This trend toward innovative biologics, improved diagnostics, and collaborative research ecosystems is fundamentally reshaping how MERS is addressed, with companies and organizations increasingly investing in scalable and targeted solutions to mitigate future outbreak risks
• The demand for advanced vaccines and antibody-based therapies is growing steadily across research-driven healthcare systems, as stakeholders prioritize long-term preventive strategies and rapid response mechanisms to control potential MERS outbreaks

Middle East Respiratory Syndrome (MERS) Market Dynamics

Driver

“Rising Focus on Infectious Disease Preparedness and Surveillance Programs”

• The increasing global emphasis on infectious disease preparedness, coupled with heightened surveillance initiatives by governments and international health organizations, is a significant driver for the growth of the MERS market
• For instance, enhanced monitoring systems and early warning frameworks established in Middle Eastern countries have improved case detection and response times, supporting demand for advanced diagnostics and therapeutic solutions
• As healthcare systems strengthen their ability to manage emerging infectious diseases, MERS-related diagnostics and investigational treatments are gaining importance in clinical and research settings. Furthermore, increased funding for pandemic preparedness is accelerating innovation in vaccines and antiviral therapies
• The growing awareness among healthcare providers regarding zoonotic diseases and cross-border transmission risks is encouraging the adoption of rapid diagnostic tools and preventive strategies. Through improved training programs and infrastructure development, countries are enhancing their capacity to manage potential outbreaks
• Rising collaboration between public health agencies and private biotechnology firms is further accelerating innovation, enabling faster development and deployment of diagnostic kits and therapeutic candidates
• Increasing international travel and trade activities are also driving the need for robust screening and monitoring systems at points of entry, thereby supporting demand for MERS detection and prevention solutions
• The need for rapid diagnosis, effective treatment options, and coordinated public health responses is propelling investments in MERS-related technologies across both developed and emerging economies. The integration of advanced laboratory networks further supports timely identification and containment of infections

Restraint/Challenge

“Limited Approved Therapies and High Development Uncertainty”

• The limited availability of approved and widely commercialized therapies for MERS, combined with the sporadic nature of outbreaks, poses a significant challenge to sustained market growth and large-scale investment
• For instance, most MERS treatments remain in investigational stages, with no fully established standardized therapeutic protocol, which creates uncertainty for pharmaceutical companies and investors
• The rarity and geographically concentrated occurrence of MERS cases make it difficult to conduct large-scale clinical trials, slowing down the development and regulatory approval of new drugs and vaccines. Furthermore, fluctuating case numbers reduce the commercial attractiveness of developing dedicated treatments
• Regulatory complexities and stringent approval requirements for infectious disease therapeutics add additional barriers, as developers must demonstrate both safety and efficacy under limited patient availability. Through prolonged development timelines and high R&D costs, market entry becomes challenging for new players
• Limited awareness and inconsistent healthcare infrastructure in certain regions further hinder early diagnosis and reporting, impacting the overall effectiveness of treatment strategies and market expansion
• Dependence on government and institutional funding for research also creates uncertainty, as funding levels may fluctuate based on shifting public health priorities and outbreak severity
• Addressing these challenges requires sustained funding, global collaboration, and adaptive clinical trial designs to ensure progress in therapy and vaccine development, while also balancing economic feasibility and public health priorities

Middle East Respiratory Syndrome (MERS) Market Scope

The market is segmented on the basis of product, route of administration, end-users, and distribution

• By Product

On the basis of product, the MERS market is segmented into REGN3048, REGN3051, GLS-5300, and others. The Others segment dominated the market with the largest market revenue share in 2025, driven by the presence of a broader range of investigational therapies, supportive care treatments, and emerging pipeline candidates beyond the leading named products. These include alternative monoclonal antibodies, antiviral compounds, and adjunct therapies that are being explored in research and clinical settings. The dominance of this segment is also supported by the limited commercialization of specific branded candidates, resulting in a diversified portfolio of experimental and supportive solutions being utilized across regions. In addition, ongoing research collaborations and government-funded programs continue to expand the scope of this segment, making it the most widely represented category in the current MERS landscape.

The GLS-5300 segment is anticipated to witness the fastest growth rate during the forecast period, fueled by increasing interest in DNA vaccine platforms and their potential to induce strong and durable immune responses. GLS-5300 has gained attention due to its vaccine-based approach, which is particularly relevant for long-term prevention strategies in high-risk populations. Growing investments in vaccine development, along with successful preclinical and early-stage clinical evaluations, are supporting its growth trajectory. Furthermore, rising emphasis on pandemic preparedness and preventive healthcare is accelerating adoption of vaccine candidates over therapeutic-only approaches.

• By Route of Administration

On the basis of route of administration, the MERS market is segmented into oral, parenteral, and others. The parenteral segment dominated the market with the largest share of 70.2% in 2025, driven by the widespread use of injectable biologics such as monoclonal antibodies and vaccine candidates that require intravenous or intramuscular delivery. Parenteral administration ensures rapid bioavailability and direct systemic action, which is critical in managing severe viral infections like MERS. Many investigational therapies are designed for parenteral delivery due to their molecular structure and need for controlled dosing. In addition, healthcare professionals prefer injectable routes in clinical and hospital settings for precise administration and immediate therapeutic response. The dominance of this segment is further supported by ongoing clinical trials focusing on biologics that are inherently suited for parenteral use.

The oral segment is expected to witness the fastest growth rate during the forecast period, driven by increasing research into small-molecule antivirals that can be administered orally for ease of use and patient compliance. Oral therapies offer significant advantages in outpatient and homecare settings, reducing the need for hospital visits and specialized administration. Growing demand for non-invasive treatment options, along with advancements in drug formulation technologies, is encouraging the development of oral antiviral candidates. Furthermore, oral medications are particularly attractive for large-scale distribution during outbreaks due to their convenience, scalability, and cost-effectiveness.

• By End-Users

On the basis of end-users, the MERS market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the market with the largest share in 2025, driven by the critical need for specialized care, isolation facilities, and advanced diagnostic infrastructure required for managing MERS patients. Hospitals serve as the primary centers for diagnosis, treatment, and containment of infectious diseases, making them the central point of care for MERS cases. The availability of intensive care units, trained healthcare professionals, and advanced laboratory equipment supports effective disease management in hospital settings. In addition, hospitals play a key role in conducting clinical trials and implementing government-led infectious disease response programs.

Espera-se que o segmento de cuidados domiciliares apresente a taxa de crescimento mais rápida durante o período de previsão, impulsionado pela crescente adoção de soluções de monitoramento remoto e pelo manejo de casos leves fora do ambiente hospitalar. Os avanços em telemedicina, kits de diagnóstico domiciliar e dispositivos de monitoramento portáteis estão permitindo que os pacientes recebam cuidados em ambientes não clínicos. O aumento dos custos da saúde e a necessidade de reduzir a sobrecarga hospitalar durante surtos também estão incentivando os modelos de cuidados domiciliares. Além disso, a maior conscientização e disponibilidade de opções de cuidados de suporte em casa estão contribuindo para o crescimento desse segmento, principalmente para pacientes com condições leves ou em recuperação.

• Por canal de distribuição

Com base no canal de distribuição, o mercado de MERS é segmentado em farmácia hospitalar, farmácia de varejo e farmácia online. O segmento de farmácia hospitalar dominou o mercado com a maior participação em 2025, visto que a maioria dos tratamentos, diagnósticos e medicamentos experimentais relacionados à MERS são administrados em ambientes hospitalares. As farmácias hospitalares estão diretamente ligadas às unidades de internação, garantindo a disponibilidade oportuna de medicamentos e produtos biológicos essenciais para o tratamento agudo. Elas também desempenham um papel fundamental no gerenciamento da distribuição controlada de medicamentos experimentais utilizados em ensaios clínicos. A aquisição centralizada e a rigorosa supervisão regulatória nos hospitais reforçam ainda mais a dominância desse segmento no mercado de MERS.

O segmento de farmácias online deverá apresentar o crescimento mais rápido durante o período de previsão, impulsionado pela crescente digitalização na área da saúde e pela adoção cada vez maior de plataformas de e-commerce para a distribuição de medicamentos. As farmácias online oferecem conveniência, maior acessibilidade e entrega eficiente de medicamentos, principalmente em regiões com acesso limitado a farmácias físicas. A integração de plataformas de saúde digital, juntamente com a crescente preferência do consumidor por serviços sem contato, está acelerando o crescimento desse segmento. Além disso, os avanços na logística e nos marcos regulatórios que dão suporte às vendas online de medicamentos contribuem ainda mais para sua rápida expansão.

Análise Regional do Mercado da Síndrome Respiratória do Oriente Médio (MERS)

• A América do Norte dominou o mercado da Síndrome Respiratória do Oriente Médio (MERS) com a maior participação na receita, de 40% em 2025, impulsionada por uma forte infraestrutura de P&D, recursos avançados de biotecnologia e participação ativa em ensaios clínicos.
• Os sistemas de saúde e os governos da região dão grande ênfase ao diagnóstico rápido, à contenção de surtos e ao rastreamento epidemiológico, o que sustenta a demanda por soluções avançadas de testes, terapias experimentais e medidas preventivas.
• Essa ampla atenção é ainda mais reforçada por investimentos contínuos em infraestrutura de saúde, iniciativas de monitoramento transfronteiriço de doenças e colaborações com organizações internacionais de saúde, estabelecendo o Oriente Médio como o principal centro de pesquisa, vigilância e atividades de resposta relacionadas à MERS.

Análise de Mercado da Síndrome Respiratória do Oriente Médio (MERS) nos EUA

O mercado de MERS nos EUA representou uma parcela significativa em 2025, impulsionado por fortes capacidades de pesquisa e desenvolvimento, infraestrutura de saúde avançada e participação ativa em programas de vigilância e preparação para doenças infecciosas. A região se beneficia de investimentos substanciais de agências governamentais e empresas de biotecnologia no desenvolvimento de testes diagnósticos, anticorpos monoclonais e vacinas candidatas contra o MERS-CoV. Além disso, a presença de empresas farmacêuticas líderes e instituições de pesquisa acadêmica fomenta a inovação e acelera os ensaios clínicos, enquanto estruturas regulatórias robustas garantem a segurança e a eficácia das soluções emergentes. A alta adoção de ferramentas avançadas de diagnóstico molecular e bioinformática fortalece ainda mais a posição da região no mercado global de MERS.

Análise de Mercado da Síndrome Respiratória do Oriente Médio (MERS) na Europa

Prevê-se que o mercado europeu de MERS cresça a uma taxa composta de crescimento anual (CAGR) constante durante o período de previsão, impulsionado principalmente por políticas de saúde pública rigorosas, sistemas robustos de monitoramento de doenças infecciosas e infraestrutura de saúde bem estabelecida. Os países europeus priorizam a detecção precoce e o controle de doenças infecciosas por meio de esforços coordenados entre agências nacionais de saúde e organizações de pesquisa. O aumento do financiamento para o preparo para pandemias e iniciativas de colaboração transfronteiriça está apoiando o desenvolvimento de tecnologias de diagnóstico avançadas e soluções terapêuticas. Além disso, a crescente conscientização sobre doenças zoonóticas e a integração de sistemas de saúde digitais estão incentivando a adoção de métodos de teste rápidos e estratégias aprimoradas de gerenciamento de pacientes em hospitais e laboratórios.

Análise de Mercado da Síndrome Respiratória do Oriente Médio (MERS) no Reino Unido

Prevê-se que o mercado de MERS no Reino Unido cresça a uma taxa composta de crescimento anual (CAGR) notável durante o período de previsão, impulsionado por uma infraestrutura de saúde pública robusta, programas de vigilância ativa e a ênfase do país na preparação para doenças infecciosas. Instituições como o Serviço Nacional de Saúde (NHS) desempenham um papel crucial na implementação de protocolos de diagnóstico, estratégias de resposta a surtos e estruturas de gestão de pacientes para infecções emergentes. A participação do Reino Unido em colaborações globais de pesquisa e estudos clínicos também contribui para a inovação em diagnósticos e terapias para MERS. Além disso, o aumento dos investimentos em pesquisa biomédica e a crescente conscientização entre os profissionais de saúde contribuem para aprimorar as capacidades de detecção e resposta no país.

Germany Middle East Respiratory Syndrome (MERS) Market Insight

The Germany MERS market is expected to expand at a considerable CAGR during the forecast period, driven by the country’s advanced healthcare system, strong emphasis on research and innovation, and well-developed laboratory infrastructure. Germany’s focus on precision medicine and high-quality diagnostic solutions supports the adoption of molecular testing technologies for infectious diseases. Collaborative efforts between academic institutions, government agencies, and biotechnology companies are fostering the development of novel therapeutic approaches and diagnostic platforms. Furthermore, the country’s commitment to healthcare digitization and data-driven decision-making enhances its ability to monitor and respond to potential outbreaks effectively.

Asia Pacific Middle East Respiratory Syndrome (MERS) Market Insight

The Asia-Pacific MERS market is poised to grow at the fastest CAGR during the forecast period, driven by rapid urbanization, expanding healthcare infrastructure, and increasing government initiatives to strengthen infectious disease preparedness. Countries such as China, Japan, and India are investing heavily in surveillance systems, laboratory networks, and research collaborations to enhance early detection and response capabilities. The region is also witnessing growing participation in global clinical trials and research programs focused on vaccine and therapeutic development. In addition, rising awareness of zoonotic diseases, coupled with improvements in diagnostic accessibility, is supporting the expansion of the MERS market across both developed and emerging economies.

Japan Middle East Respiratory Syndrome (MERS) Market Insight

The Japan MERS market is gaining momentum due to the country’s technologically advanced healthcare system, strong focus on infection control, and high level of preparedness for emerging infectious diseases. Japan’s integration of molecular diagnostics, digital health technologies, and automated laboratory systems enhances its ability to detect and manage MERS cases efficiently. The country’s aging population further drives demand for effective diagnostic tools and supportive care solutions in both hospital and homecare settings. Moreover, Japan’s active participation in international research collaborations contributes to advancements in vaccine development and therapeutic research targeting MERS-CoV.

India Middle East Respiratory Syndrome (MERS) Market Insight

The India MERS market accounted for a notable share in Asia-Pacific in 2025, driven by rapid healthcare infrastructure development, increasing awareness of infectious diseases, and growing adoption of advanced diagnostic technologies. Government initiatives aimed at strengthening disease surveillance systems and improving public health preparedness are playing a key role in market expansion. India’s large population base, coupled with rising healthcare expenditure and increasing participation of domestic biotechnology firms, supports the development and accessibility of diagnostic and therapeutic solutions. In addition, the country’s growing network of laboratories and expansion of healthcare services in urban and semi-urban areas are enhancing its capability to detect and manage infectious diseases effectively.

Middle East Respiratory Syndrome (MERS) Market Share

The Middle East Respiratory Syndrome (MERS) industry is primarily led by well-established companies, including:

• INOVIO Pharmaceuticals (U.S.)
• GeneOne Life Science Inc. (South Korea)
• International Vaccine Institute (South Korea)
• Coalition for Epidemic Preparedness Innovations (International)
• Walter Reed Army Institute of Research (U.S.)
• Samsung Life Public Welfare Foundation (South Korea)
• VGXI, Inc. (U.S.)
• National Institutes of Health (U.S.)
• National Institute of Allergy and Infectious Diseases (U.S.)
• University of Pennsylvania (U.S.)
• The Wistar Institute (U.S.)
• DARPA (U.S.)
• Korea National Institute of Health (South Korea)
• Beijing Advaccine Biotechnology Co., Ltd. (China)
• Centers for Disease Control and Prevention (U.S.)
• World Health Organization (International)
• Korea Basic Science Institute (South Korea)
• Korea Research Institute of Bioscience and Biotechnology (South Korea)
• GSK (U.K.)
• Pfizer Inc. (U.S.)

What are the Recent Developments in Global Middle East Respiratory Syndrome (MERS) Market?

• In January 2026, results from human Phase 1 trials of MERS-CoV vaccine candidates (including MVA-MERS-S and others) demonstrated safety and immunogenicity, marking progress toward potential prophylactic solutions against MERS-CoV
• In December 2025, WHO announced that a MERS-CoV virus isolate was added to the WHO BioHub System, enabling broader research access and strengthening global preparedness and collaborative research efforts against coronaviruses
• In July 2025, research published on multivalent virus-like particle (VLP) vaccines displaying MERS-CoV and related merbecovirus antigens showed cross-reactive antibody responses in preclinical models, indicating advancements in broad-spectrum coronavirus vaccine design
• In May 2025, the Kingdom of Saudi Arabia’s Ministry of Health reported nine laboratory-confirmed MERS-CoV infections, including a cluster of cases among healthcare workers, underscoring ongoing transmission risks and the importance of infection prevention and control measures
• In March 2025, WHO published a bi-annual update noting four additional confirmed MERS-CoV cases (with two deaths) reported in Saudi Arabia between late 2024 and early 2025, highlighting that MERS-CoV continues to circulate and pose a public health threat

SKU-53782